Francesca Branzoli1,2, Małgorzata Marjańska3. 1. Institut du Cerveau - ICM, Centre de Neuroimagerie de Recherche - CENIR. 2. ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Paris, France. 3. Center for Magnetic Resonance Research, Department of Radiology, University of Minnesota, Minneapolis, Minnesota, USA.
Abstract
PURPOSE OF REVIEW: Magnetic resonance spectroscopy (MRS) may play a key role for the management of patients with glioma. We highlighted the utility of MRS in the noninvasive diagnosis of gliomas with mutations in isocitrate dehydrogenase (IDH) genes, by providing an overview of the neurochemical alterations observed in different glioma subtypes, as well as during treatment and progression, both in vivo and ex vivo. RECENT FINDINGS: D-2-hydroxyglutarate (2HG) decrease during anticancer treatments was recently shown to be associated with altered levels of other metabolites, including lactate, glutamate and glutathione, suggesting that tumour treatment leads to a metabolic reprogramming beyond 2HG depletion. In combination with 2HG quantification, cystathionine and glycine seem to be the most promising candidates for higher specific identification of glioma subtypes and follow-up of disease progression and response to treatment. SUMMARY: The implementation of advanced MRS methods in the routine clinical practice will allow the quantification of metabolites that are not detectable with conventional methods and may enable immediate, accurate diagnosis of gliomas, which is crucial for planning optimal therapeutic strategies and follow-up examinations. The role of different metabolites as predictors of patient outcome still needs to be elucidated.
PURPOSE OF REVIEW: Magnetic resonance spectroscopy (MRS) may play a key role for the management of patients with glioma. We highlighted the utility of MRS in the noninvasive diagnosis of gliomas with mutations in isocitrate dehydrogenase (IDH) genes, by providing an overview of the neurochemical alterations observed in different glioma subtypes, as well as during treatment and progression, both in vivo and ex vivo. RECENT FINDINGS: D-2-hydroxyglutarate (2HG) decrease during anticancer treatments was recently shown to be associated with altered levels of other metabolites, including lactate, glutamate and glutathione, suggesting that tumour treatment leads to a metabolic reprogramming beyond 2HG depletion. In combination with 2HG quantification, cystathionine and glycine seem to be the most promising candidates for higher specific identification of glioma subtypes and follow-up of disease progression and response to treatment. SUMMARY: The implementation of advanced MRS methods in the routine clinical practice will allow the quantification of metabolites that are not detectable with conventional methods and may enable immediate, accurate diagnosis of gliomas, which is crucial for planning optimal therapeutic strategies and follow-up examinations. The role of different metabolites as predictors of patient outcome still needs to be elucidated.
Authors: Ovidiu C Andronesi; Otto Rapalino; Elizabeth Gerstner; Andrew Chi; Tracy T Batchelor; Dan P Cahill; A Gregory Sorensen; Bruce R Rosen Journal: J Clin Invest Date: 2013-09-03 Impact factor: 14.808
Authors: Morteza Esmaeili; Bob C Hamans; Anna C Navis; Remco van Horssen; Tone F Bathen; Ingrid S Gribbestad; William P Leenders; Arend Heerschap Journal: Cancer Res Date: 2014-07-08 Impact factor: 12.701
Authors: Changho Choi; Sandeep K Ganji; Ralph J DeBerardinis; Kimmo J Hatanpaa; Dinesh Rakheja; Zoltan Kovacs; Xiao-Li Yang; Tomoyuki Mashimo; Jack M Raisanen; Isaac Marin-Valencia; Juan M Pascual; Christopher J Madden; Bruce E Mickey; Craig R Malloy; Robert M Bachoo; Elizabeth A Maher Journal: Nat Med Date: 2012-01-26 Impact factor: 53.440
Authors: Zachary J Reitman; Genglin Jin; Edward D Karoly; Ivan Spasojevic; Jian Yang; Kenneth W Kinzler; Yiping He; Darell D Bigner; Bert Vogelstein; Hai Yan Journal: Proc Natl Acad Sci U S A Date: 2011-02-02 Impact factor: 12.779
Authors: C Houillier; X Wang; G Kaloshi; K Mokhtari; R Guillevin; J Laffaire; S Paris; B Boisselier; A Idbaih; F Laigle-Donadey; K Hoang-Xuan; M Sanson; J-Y Delattre Journal: Neurology Date: 2010-10-26 Impact factor: 11.800
Authors: Patrick S Ward; Chao Lu; Justin R Cross; Omar Abdel-Wahab; Ross L Levine; Gary K Schwartz; Craig B Thompson Journal: J Biol Chem Date: 2012-12-21 Impact factor: 5.486
Authors: Thomas C Booth; Evita C Wiegers; Esther A H Warnert; Kathleen M Schmainda; Frank Riemer; Ruben E Nechifor; Vera C Keil; Gilbert Hangel; Patrícia Figueiredo; Maria Del Mar Álvarez-Torres; Otto M Henriksen Journal: Front Oncol Date: 2022-02-28 Impact factor: 5.738